Perspectives & Practice Insights
Clinical commentary, education, and community stories from across the Alliance.
FDA Approves OTC Differin® Epiduo® for Acne Management
Galderma has announced that the U.S. Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5%) for over-the-counter (OTC) use in individuals aged 12 years and older.
FDA Approves ZORYVE® (roflumilast) Cream 0.05% for Atopic Dermatitis in Young Children Ages 2-5
Arcutis Biotherapeutics, Inc. has announced the FDA approval of ZORYVE® (roflumilast) cream 0.05% for the treatment of mild to moderate atopic dermatitis in children aged 2 to 5 years.
Oct 12, 2025Novartis Receives FDA Approval for Rhapsido® (Remibrutinib) as a Novel Treatment for Chronic Spontaneous Urticaria
On September 30, 2025, Novartis announced the FDA approval of Rhapsido® (remibrutinib), marking it as the first oral Bruton’s tyrosine kinase inhibitor (BTKi) approved for the treatment of chronic spontaneous urticaria (CSU) in adults who remain symptomatic…
Oct 11, 2025FDA Approves TREMFYA® for Pediatric Psoriasis and Psoriatic Arthritis
In a significant advancement for pediatric care, the U.S. Food and Drug Administration (FDA) has approved TREMFYA (guselkumab) for the treatment of children aged 6 years and older with moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis…
Oct 09, 2025Efficacy and Safety of Ruxolitinib Cream in Pediatric Atopic Dermatitis: TRuE-AD3 Study Findings
A phase 3 study (TRuE-AD3) evaluated the efficacy and safety of ruxolitinib cream in children aged 2-11 years with mild-to-moderate atopic dermatitis (AD).
Oct 03, 2025FDA Approves Otezla® for Pediatric Psoriatic Arthritis in Patients 6 Years and Older
The FDA has granted approval for Otezla® (apremilast) to treat active psoriatic arthritis in pediatric patients aged 6 years and older who weigh at least 20 kg.
Aug 15, 2025The efficacy of longer-term lebrikizumab treatment
This study evaluated the long-term efficacy of lebrikizumab in patients with moderate-to-severe atopic dermatitis who did not meet early treatment response criteria by week 16.
Jun 17, 2025Rilzabrutinib Shows Promise for Treating Tough Cases of Chronic Spontaneous Urticaria
The phase 2 RILECSU clinical trial has brought encouraging news for patients suffering from chronic spontaneous urticaria (CSU) that doesn’t respond well to standard antihistamines.
Jun 03, 2025Topical steroid withdrawal diagnostic criteria defined by NIH researcher
Researchers at the National Institutes of Health (NIH) have uncovered new insights into dermatitis caused by topical steroid withdrawal (TSW), revealing that it is distinct from eczema and linked to high levels of a key chemical compound called nicotinamide…
May 05, 2025Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-Year Long Term Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials Including Laboratory Parameters
Deucravacitinib demonstrated a consistent safety profile over 5 years with more than 5,000 patient years of exposure, showing no increase in adverse events, serious adverse events, or the emergence of new safety signals.
Apr 28, 2025Lebrikizumab Improves Itch, Itch Interference on Sleep, and Skin Pain in Patients With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
In the open-label ADapt trial, lebrikizumab demonstrated significant improvements in managing symptoms of AD like itch, sleep disruption due to itching, and skin pain in patients who had previously been treated with dupilumab.
Apr 15, 2025
Enhance Your Clinical Expertise: Learn About Immunology at the Upcoming RAPIDS Conference
As a dermatology physician assistant (PA), staying at the forefront of clinical advancements is key to providing the best care for your patients.
Jan 11, 2025
Characterizing Loss of Response to Baricitinib for AA in a Small Number of Patients Over 3 Years
A small cohort of 12 patients undergoing long-term maintenance therapy with baricitinib 4-mg for alopecia areata experienced true loss of response (defined as loss of SALT Score ≤ 20 at week 152).
Nov 26, 2024
PROSES Study Evaluating Impact of Sarecycline
PROSES Study Evaluating Impact of Sarecycline
Nov 18, 2024
Study Update: Exploring the PROAK Study: Tirbanibulin for Actinic Keratosis
The Patient-Reported Outcomes in Actinic Keratosis (PROAK) study investigated the effectiveness and safety of tirbanibulin 1% ointment among adults with actinic keratosis (AK) on the face or scalp.
Oct 19, 2024
Medication Update: ZORYVE®(roflumilast) Foam
The FDA has accepted Arcutis Biotherapeutics' Supplemental New Drug Application for ZORYVE® (roflumilast) foam for scalp and body psoriasis in patients aged 12 and older.
Oct 12, 2024
Robert Higham, MPAS, PA-C Executive Director Clinical Development Arcutis with Eileen Cheever, PA-C
Video interview: Robert Higham, MPAS, PA-C Executive Director Clinical Development Arcutis with Eileen Cheever, PA-C.
Feb 22, 2024
Video Blog: Raising Awareness of the Emotional and Physical Impact of Plaque Psoriasis
Robert Heim of Arcutis discusses the Skin Insight Survey and what 507 psoriasis patients revealed about the physical and emotional toll of the disease — including the frequent miss of intertriginous involvement.
Mar 24, 2023
Hyaluronic Filler Comparisons
Hyaluronic acid (HA) is a naturally-occurring sugar molecule found primarily in the dermis, connective tissues, and the eyes.
Feb 04, 2023
Elevate Comparing Neurotoxins
Since the early 2000s, botulinum toxins – colloquially known as “Botox” – have surged in popularity. Many people receive regular injections of these neurotoxins for cosmetic and medical reasons.
Sep 22, 2022New FDA Approval of Galderma’s SCULPTRA Label Means More Choice for Aesthetic Providers
The newly approved SCULPTRA label has exciting implications for clinicians. Swiss pharmaceutical company Galderma has received new FDA approval for an expanded label on injectable poly-L-lactic acid (or PLLA) product SCULPTRA, allowing…
May 09, 2022
Video Interview Brittany Craiglow MD on Systemic Therapies in Pediatric Dermatology
Brittany Craiglow, MD, on how dupilumab reshaped her approach to pediatric atopic dermatitis, how psoriasis presents differently in kids, and practical tips for injecting young patients.
Mar 25, 2022
Acne and Rosacea Mimickers
Joslyn Kirby, MD, on when acne isn't just acne — the mimickers worth a second look, plus practical tips for maskne and whey protein–triggered breakouts.
Mar 08, 2022
Brett King MD discusses Janus Kinase Inhibitor Use in Dermatology
Brett King, MD, explains where the JAK inhibitor boxed warning actually came from and why dermatology patients aren't the population it describes.
Feb 18, 2022
Video Interview on COVID19 Cutaneous Manifestations
Doug walks through the cutaneous signs of COVID-19 — from early oral and morbilliform eruptions to the well-documented "COVID toes" — and the skin reactions seen after vaccination.
Feb 04, 2022
Ipledge Program Update 2021
Could it get any crazier? Sure, it can, thanks to system changes and updates in the IPledge “Committed to Pregnancy Prevention” Program. When are all the updates happening? Right in the middle of the chaos—the middle of December. Not to worry.
Nov 30, 2021
Modern Acne Rosacea and HS Management Strategies
Spotlight: Modern Acne, Rosacea, and HS Management Strategies by Jennifer Conner MPAS, PA-C, Keri Holyoak MPH, MSHS, PA-C, and Vicki Roberts MPAS, PA-C
Oct 15, 2021
Anti-OX40: A New Frontier in Atopic Dermatitis Management?
The development of new treatments for atopic dermatitis aim to provide disease control and thus improve the overall burden of disease.
Oct 12, 2021
Antibiotic Stewardship
Panel Discussion: Antibiotic Stewardship Strategies in 2020 by Ted Rosen MD, James Treat MD, and Douglas DiRuggiero DMSC, PA-C
Oct 08, 2021
Isotretinoin in 2020
Isotretinoin in 2020 by James Treat MD
Sep 03, 2021
Which Biologic & When
Psoriasis: Which Biologic & When by Craig Teller MD
Aug 27, 2021
Literature Update 2020
Literature Update 2020 by Ted Rosen MD
Aug 20, 2021
Beyond JAKs SIK Inhibitors
In fact, a Belgium-based company, Galapagos Pharmaceuticals, recently reported preliminary data on its salt-inducible kinase (SIK) therapy, GLPG3970; which is part of their multi-indication SIK inhibitor development program that seeks to “rebalance between…
Aug 06, 2021
Therapeutic Potential Cannabinoids in Dermatology
From Bud to Breakthrough: The Therapeutic Potential and Current Landscape of Cannabinoids in Dermatology by Adam Friedman MD
Aug 06, 2021
Pre-Biologic Treatment Options for Psoriasis
Pre-Biologic Treatment Options for Psoriasis by John Koo MD
Jul 23, 2021
Psychderm Delusions and Solutions
PsychDerm: Delusions and Solutions by John Koo MD
Jul 16, 2021
Cutaneous Reactions and the COVID-19 Vaccine
Clinical trials for both vaccines noted the potential for cutaneous reactions after vaccination, but these reactions were not fully characterized.
Jun 06, 2021
Will Moderna’s COVID-19 Vaccine Cause Side Effects in People with Facial Fillers?
Unless you are one of the lucky few with no TV or social media, you have most certainly heard of the reported risk of facial-filler swelling associated with the Moderna COVID-19 vaccine.
Mar 07, 2021
Payment Transparency NPs PAs Dermatology
The Open Payment program by the Centers for Medicare and Medicaid Services’ (CMS) will be updated in 2021 to include five new provider types: Physician assistants, Nurse practitioners, Clinical nurse specialists, Certified registered nurse anesthetists…
Dec 30, 2020